When was tirzepatide created, and how did it go from lab to licensed medicine?

What research problem was tirzepatide designed to solve?

For decades, researchers studying obesity and type 2 diabetes knew that two gut hormones (GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)) each played a role in regulating appetite and insulin response after eating. GLP-1 was the more studied of the two, and medicines targeting it alone had already reached the clinic. But Eli Lilly's scientists asked a different question: what would happen if a single molecule activated both receptors at once?

The answer required designing what chemists call a dual agonist, a compound shaped to fit and stimulate two distinct receptor proteins. Early preclinical work showed that combining GIP and GLP-1 activity produced stronger effects on appetite suppression and glucose regulation than either pathway alone. That finding shaped the entire development strategy. You can read more about who specifically created tirzepatide and the Eli Lilly team behind it on a companion page.

It is worth noting that this dual mechanism is genuinely distinct from how older GLP-1 medicines work, it is not simply a higher dose of an existing drug. The structural novelty was part of why tirzepatide went through extensive clinical testing before any licence was granted.

When did tirzepatide move from animal studies into human trials?

Phase 1 human studies for tirzepatide began in the mid-2010s, establishing safety and tolerability in small cohorts. Phase 2 trials followed, refining the dosing schedule and confirming that the weekly subcutaneous injection format was practical for patients. The SURPASS programme (a large series of phase 3 trials focused on type 2 diabetes) ran from around 2019 to 2021, and the SURMOUNT programme, focused on weight management in people without diabetes, ran from 2019 to 2022.

SURMOUNT-1, the flagship weight-management trial, randomised 2,539 adults with obesity across those years. Its results, published in the New England Journal of Medicine in 2022, showed average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, a figure that drew considerable attention from clinicians. The SURMOUNT programme as a whole, combined with the SURPASS diabetes trials, involved more than 10,000 participants across its studies.

Planning your food approach alongside treatment is a separate but equally practical question, our guide on what to eat when taking tirzepatide covers that in detail.

When was tirzepatide licensed in the UK, and how does NICE fit in?

The MHRA granted tirzepatide its first UK marketing authorisation for type 2 diabetes management in 2022, under the Mounjaro brand name. The weight-management licence followed, covering adults with a BMI of 30 or above, or 27 and above where a weight-related condition such as hypertension, high cholesterol or obstructive sleep apnoea is present.

NICE published its technology appraisal (TA1026) on 23 December 2024, recommending tirzepatide for NHS use in adults with a BMI of 35 or above plus at least one weight-related comorbidity, with the NHS rolling out access in phased cohorts from 2025. Lower BMI thresholds apply for people from some ethnic backgrounds under UK guidance. The full NICE appraisal sets out the evidence the committee reviewed and the conditions for NHS use.

Tirzepatide carries a Black Triangle (▼) in the UK, a standard designation for newer medicines requiring additional monitoring. That does not mean the medicine is considered unsafe, it means the MHRA collects extra post-market data during its early years of widespread use. For a broader look at how Mounjaro's history connects to the wider context of weight-loss medicines, this page on Mounjaro's creation adds useful background.

Does the age of a medicine matter when thinking about starting it?

It is a sensible thing to wonder about, especially if you are considering a medicine that has only been widely prescribed for a few years. The honest answer is that the length of a medicine's clinical record matters, but so does the quality of that record, and tirzepatide's phase 3 programme was among the largest and most rigorously designed in obesity medicine's history.

That said, a newer medicine's long-term data will, by definition, be thinner than a drug prescribed for 20 years. The MHRA's Black Triangle monitoring system exists precisely to catch any signals that emerge as millions of people use it in real-world conditions. Clinicians weigh that picture when assessing suitability for individual patients. Practical details about what to eat alongside treatment (protein adequacy, hydration, managing the appetite changes the medicine brings) matter just as much as the science, and our meal ideas for people on tirzepatide page is a good starting point there.

If you are weighing up whether tirzepatide might be appropriate for you, that conversation happens at a clinical consultation. Our weight-loss treatment overview explains the private route clearly, and if private costs are a factor, the Mounjaro price comparison page gives honest UK market context. When you are ready, check your eligibility with our prescribers.